Genetic variants of <it>NOXA</it> and <it>MCL1</it> modify the risk of HPV16-associated squamous cell carcinoma of the head and neck

• Main Authors: Zhou Ziyuan, Sturgis Erich M, Liu Zhensheng, Wang Li-E, Wei Qingyi, Li Guojun
• Format: Article
• Language: English
• Published: BMC 2012-05-01
• Series: BMC Cancer
• Subjects: <it>NOXA</it>; <it>MCL1</it>; HPV16; Genetic susceptibility; Squamous cell carcinoma of the head and neck
• Online Access: http://www.biomedcentral.com/1471-2407/12/159

<p>Abstracts</p> <p>Background</p> <p>The cooperation between phorbol 12-myristate 13-acetate induced protein 1 (NOXA) and myeloid cell leukemia 1 (MCL1) is critical in the intrinsic apoptotic pathway. Human papillomavirus 16 (HPV16), by inducing p53 and pRb-E2F degradation, may play an essential role in development of squamous cell carcinoma of the head and neck (SCCHN) through NOXA-MCL1 axis-mediated apoptosis. Therefore, genetic variants of <it>NOXA</it> and <it>MCL1</it> may modify the SCCHN risk associated with HPV16 seropositivity.</p> <p>Methods</p> <p>HPV16 serology was obtained by immunoadsorption assay. Four functional SNPs in the promoter of <it>NOXA</it> (rs9957673, rs4558496) and <it>MCL1</it> (rs9803935, rs3738485) were genotyped for 380 cases and 335 frequency-matched cancer-free controls of non-Hispanic whites.</p> <p>Results</p> <p>Associations between the four polymorphisms and SCCHN risk were not significant, while we observed a significantly joint effect on SCCHN risk between the polymorphisms and HPV16 seropositivity. Notably, this effect modification was particularly pronounced for oropharyngeal cancer in subgroups including never smokers, never drinkers and younger subjects.</p> <p>Conclusions</p> <p>Our results suggested that polymorphisms of <it>NOXA</it> and <it>MCL1</it> may modify the risk of HPV16-associated oropharyngeal cancer. The further identification of population subgroups at higher risk provides evidence that HPV-targeting treatment may help benefit SCCHN. However, larger studies are needed to validate our findings.</p>